Browse drugs

… followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment seque…

…Skin was the most common site of primary malignancy (n=67;62%). Pembrolizumab (n=44;40.7%) and Ipilimumab/Nivolumab in combination (n=44;40.7…

…ith filters for RCTs. We restricted our analysis to ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab …

…hort 1 has 43 patients all with HLA A2 receiving ipilimumab and nivolumab with 10 doses of intra-muscular SCIB1 over 24-months. Cohort 3 …

…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…

…59(6371):97–103.Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced NSCLC. N Engl J Med. 2019;381(21):2…

…, Wai ES, et al. Survival outcomes following discontinuation of ipilimumab and nivolumab for advanced melanoma in a population-based cohor…

…de combination ipilimumab and nivolumab, nivolumab monotherapy, pembrolizumab, and combination relatimab and nivolumab. Regarding hospitaliza…

…77.0412Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J M…

…on E, Sondak VK, Ribas A. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023 Mar 2;388(9):813-823.B…

…(42.6%) did not. The most frequently administered regimens were ipilimumab, nivolumab, and pembrolizumab, with or without platinum-based c…

…in J; CheckMate 067 Investigators. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1)…